Dr. Marek Kozlowski

Marek Kozlowski (PhD) combines 20 years of experience in research, industry and company building across life science and healthcare with a focus on therapeutics, diagnostics and research tools. He is currently a Senior Investment Director at NRW.Venture and a board director at 4TEEN4 Pharmaceuticals, Abalos Therapeutics, SphingoTec, Resolve Biosciences and Emergence Therapeutics (sold in 2023). Marek is trained as biotechnologist (MScEng, Warsaw University) and molecular biologist (PhD, European Molecular Biology Laboratory, Ludwig Maximilians University).